Drug Trial Radar · NCT04130802
OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
153
Actual
Start
Sep 27, 2019
Primary completion
Jan 31, 2020
Study completion Jan 31, 2020
Sponsor
- Lead sponsor
- OculisIndustry
- Sponsor type
- Industry
- First posted
- Oct 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract surgery. The primary objective is to evaluate the efficacy and safety of OCS-01 compared to placebo and the secondary objective is to evaluate the optimal dosing frequency (once a day \[QD\] or twice a day \[BID\]).
Conditions
- Inflammation Corneal
- Pain, Postoperative
Interventions
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mLDrug
OCS-01 eye drops
PlaceboDrug
Vehicle eye drops
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Absence of Anterior Chamber Cells (i.e. Score of '0')Time frame: at Day 15 (visit 6)
- Number of Subjects With Absence of Ocular Pain (i.e. Score of '0')Time frame: at Day 4 (visit 4)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Medical cennre
Petaluma, California
Medical center
Roseburg, Oregon
Medical center
Houston, Texas
Medical center
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.